Oncolytic herpes simplex virus−1 (oHSV) can boost anti-tumor immune responses in gliomas. Here the authors report that CD4 + T cells are required for the therapeutic activity of an oHSV-engineered to express IL-12 in preclinical glioblastoma models.
- Jeffrey M. Grimes
- Sadashib Ghosh
- Jianmei W. Leavenworth
